Cytochalasin B (Synonyms: 细胞松弛素B; Phomin)

目录号: HY-16928 纯度: 99.78%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Cytochalasin B 是一种能透过细胞的真菌毒素，能够与肌动蛋白丝的有刺端结合，扰乱肌动蛋白聚合物的形成，对 F-actin 的 K_d 值为 1.4-2.2 nM。Cytochalasin B 抑制细胞迁移。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Cytochalasin B Chemical Structure

CAS No. : 14930-96-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥3590	In-stock
1 mg	￥950	In-stock
5 mg	￥4000	In-stock
10 mg	现货	询价
50 mg		询价
100 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 30 篇科研文献

: Cytochalasin B purchased from MCE. Usage Cited in: Adv Sci (Weinh). 2020 Jun 17;7(15):1903583. [Abstract]; Expression of CTC cluster-related (plakoglobin and CD44) and EMT-related (vimentin and E-cadherin, 4 days) proteins in LNCaP cells grown on different substrates after treatment with different inhibitors (Cytoskeleton B (CB), Nocodazole (NO), PF-573288 (PF), Y-27632 (Y), and (-)-Blebbistatin ((-) Bl)).

: Cytochalasin B purchased from MCE. Usage Cited in: Adv Sci (Weinh). 2020 Jun 17;7(15):1903583. [Abstract]; Immunofluorescence imaging of LNCaP cells treated with the Cytoskeleton B (CB), Nocodazole (NO), PF-573288 (PF), Y-27632 (Y), and (-)-Blebbistatin ( (-) Bl). After the cells are cultured on different substrates for 3 days, inhibitors are added and incubated for 24 h.

Cytochalasin B 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Cytochalasin B is a cell-permeable mycotoxin binding to the barbed end of actin filaments, disrupting the formation of actin polymers, with K_d value of 1.4-2.2 nM for F-actin. Cytochalasin B blocks cell migration.

IC₅₀ & Target

Kd: 2.2 nM (F-actin, with Mg²⁺), 1.4 nM (F-actin, with Mg²⁺/K⁺)^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	2.13 μM Compound: 5	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 22483395]
CHO	IC₅₀	0.26 μg/mL Compound: Cytochalasin B	Cytotoxicity against CHO cells transfected with ICAM1 by MTT assay Cytotoxicity against CHO cells transfected with ICAM1 by MTT assay	[PMID: 15165136]
HCT-116	IC₅₀	12 μM Compound: 8	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34846891]
HCT-15	IC₅₀	1.94 μM Compound: 5	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 22483395]
HEK293	IC₅₀	> 10 μM Compound: 5311281	Inhibition of the Glucose Transporter (GLUT2, SLC2A2) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A2 WT-OE cells Inhibition of the Glucose Transporter (GLUT2, SLC2A2) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A2 WT-OE cells	10.5281/zenodo.7360664
HEK293	IC₅₀	3.9 μM Compound: 5311281	Inhibition of the Glucose Transporter (GLUT3, SLC2A3) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A3 WT-OE cells Inhibition of the Glucose Transporter (GLUT3, SLC2A3) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A3 WT-OE cells	10.5281/zenodo.7360656
HEK293	IC₅₀	3.9 μM Compound: 5311281	Inhibition of the Glucose Transporter (GLUT4, SLC2A4) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A4 WT-OE cells Inhibition of the Glucose Transporter (GLUT4, SLC2A4) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A4 WT-OE cells	10.5281/zenodo.7360638
HEK293	IC₅₀	4.1 μM Compound: 5311281	Inhibition of the Glucose Transporter (GLUT1, SLC2A1) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A1 WT-OE cells Inhibition of the Glucose Transporter (GLUT1, SLC2A1) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A1 WT-OE cells	10.5281/zenodo.7360676
HeLa	IC₅₀	0.25 μg/mL Compound: Cytochalasin B	Inhibition of LFA1/ICAM1-mediated CFSE-labeled TPA-stimulated human HL60 cell adhesion to ICAM1 expressing human HeLa cells after 45 mins by fluorescence analysis Inhibition of LFA1/ICAM1-mediated CFSE-labeled TPA-stimulated human HL60 cell adhesion to ICAM1 expressing human HeLa cells after 45 mins by fluorescence analysis	[PMID: 11374943]
HeLa	IC₅₀	5.5 μg/mL Compound: cytochalasin B	Inhibition of LFA1:CD11a/CD18/ICAM1-mediated human HL60 cell adhesion to human HeLa cells expressing ICAM1 by fluorescence analysis Inhibition of LFA1:CD11a/CD18/ICAM1-mediated human HL60 cell adhesion to human HeLa cells expressing ICAM1 by fluorescence analysis	[PMID: 12880315]
HeLa	IC₅₀	7.9 μM Compound: 5	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 22483395]
HepG2	IC₅₀	9.5 μM Compound: 8	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34846891]
HL-60	IC₅₀	> 30 μg/mL Compound: cytochalasin B	Cytotoxicity against human HL60 cells by XTT assay Cytotoxicity against human HL60 cells by XTT assay	[PMID: 12880315]
HL-60	IC₅₀	> 30 μg/mL Compound: Cytochalasin B	Cytotoxicity against human HL60 cells after 7 days by XTT/PMS assay Cytotoxicity against human HL60 cells after 7 days by XTT/PMS assay	[PMID: 11374943]
HL-60	IC₅₀	40 μg/mL Compound: Cytochalasin B	Cytotoxicity against human HL60 cells by XTT assay Cytotoxicity against human HL60 cells by XTT assay	[PMID: 15165136]
MCF7	IC₅₀	5.2 μM Compound: 8	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34846891]
RAW264.7	IC₅₀	5.6 μg/mL Compound: Cytochalasin B	Inhibition of iNOS production in LPS-activated mouse RAW264.7 cells after 20 hrs Inhibition of iNOS production in LPS-activated mouse RAW264.7 cells after 20 hrs	[PMID: 15165136]
RAW264.7	IC₅₀	6.5 μg/mL Compound: Cytochalasin B	Cytotoxicity against mouse RAW264.7 cells after 2 days by MTT assay Cytotoxicity against mouse RAW264.7 cells after 2 days by MTT assay	[PMID: 15165136]
SK-MEL-2	IC₅₀	0.67 μM Compound: 5	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 22483395]
SK-OV-3	IC₅₀	0.46 μM Compound: 5	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 22483395]
XF498	IC₅₀	2.36 μM Compound: 5	Cytotoxicity against human XF498 cells after 48 hrs by SRB assay Cytotoxicity against human XF498 cells after 48 hrs by SRB assay	[PMID: 22483395]

体外研究
(In Vitro)

Cytochalasin B 是一种可穿透细胞的霉菌毒素，可与肌动蛋白丝的倒钩端结合，抑制肌动蛋白丝的伸长和缩短，在 MgCl₂（2 mM）或 MgCl₂（2 mM）加 KCl 存在下，对 F-肌动蛋白的 K_ds 分别为 2.2 nM 和 1.4 nM^[1]。Cytochalasin B（0.1-10 μM）对多种鼠癌细胞系有抑制作用，处理3小时后，IC₅₀s分别为2.56 μM（M109c）、10.46 μM（B16BL6）、105.5 μM（P388/ADR）、51.9 μM（P388/S），IC₈₀ 分别为12.23 μM（M109c）、44.86 μM（B16BL6）、188.4 μM（P388/ADR）、84.1 μM（P388/S），IC₅₀s分别为0.25 μM（M109c）、0.37 μM（B16F10）、0.87 μM（B16BL6）处理 4 天后，IC₈₀ 分别为 0.75 μM (M109c)、1.21 μM (B16F10)、10.41 μM (B16BL6)^[2]。Cytochalasin B (6 μM) 可增加肌原纤维碎裂指数 (MFI)，这是由于肌原纤维蛋白强烈断裂成短片段所致。Cytochalasin B 还可加速肌动蛋白丝的断裂。此外，Cytochalasin B 可加速 F- 肌动蛋白向 G- 肌动蛋白的转化，降低 F- 肌动蛋白的含量，并显著增加死后处理过程中的 G- 肌动蛋白条带^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Cytochalasin B（10、25、50 mg/kg，腹腔注射）剂量依赖性地延长了患有 P388/ADR 白血病的 Balb/c 小鼠的预期寿命。50 mg/kg 的 Cytochalasin B 可使多药耐药 P388/ADR 群的长期存活率提高 10%，使药物敏感的 P388/S 群的长期存活率提高 40%^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

479.61

Formula

C₂₉H₃₇NO₅

CAS 号

14930-96-2

性状

固体

颜色

White to off-white

中文名称

细胞松弛素B；松胞菌素B

结构分类

Others

初始来源

微生物

Mould

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 83.33 mg/mL (173.75 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

Ethanol 中的溶解度 : 25 mg/mL (52.13 mM; 超声助溶)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0850 mL	10.4251 mL	20.8503 mL
5 mM	0.4170 mL	2.0850 mL	4.1701 mL
10 mM	0.2085 mL	1.0425 mL	2.0850 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.21 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.21 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.21 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 玉米油中，混合均匀。
方案四

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.34 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案五

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.34 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案六

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.34 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 0.5% CMC-Na/0.5% Tween-80 in Saline water
Solubility: 5 mg/mL (10.43 mM); Suspened solution; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.84%

选择批次：

Data Sheet (657 KB) SDS (644 KB)

COA (177 KB) HNMR (316 KB) LCMS (254 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Theodoropoulos PA, et al. Cytochalasin B may shorten actin filaments by a mechanism independent of barbed end capping. Biochem Pharmacol. 1994 May 18;47(10):1875-81. [Content Brief]

[2]. Trendowski M, et al. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Invest New Drugs. 2015 Apr;33(2):290-9. [Content Brief]

[3]. Zhou C, et al. The effect of Cytochalasin B and Jasplakinolide on depolymerization of actin filaments in goose muscles during postmortem conditioning. Food Res Int. 2016 Dec;90:1-7. [Content Brief]

[4]. Liang Ma, et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015 Jan;25(1):24-38. [Content Brief]

Cell Assay ^[2]	The attached cell lines M109c, B16BL6, and B16F10 are seeded at 1 to 4 × 10⁴ cells/mL in 2 mL volumes in 24-well culture plates 1 day prior to treatment with Cytochalasin B. The suspension culture of P388/ADR cells is seeded at 5 × 10⁴ cells/mL and allowed to grow overnight before Cytochalasin B treatment. Cells are treated with Cytochalasin B for 3 h, as well as 2, 3, or 4 days. In the case of continuous exposure for 2, 3, or 4 days, attached cells are trypsinized and counted with a hemacytometer. Leukemia cell suspensions are counted with a Coulter Counter. In the case of short-term exposure, cells are washed twice with fresh medium, then trypsinized (except for P388/ADR cells), reseeded, and allowed to regrow for 3 days, at which time they are counted. Growth results are calculated as the number of cells generated above the seeding density compared to the untreated control cells and graphically presented as percent of control increase^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Mice^[2] For chemotherapy testing, Balb/c mice under isoflurane anesthesia are challenged with 2 × 10⁵ trypan blue negative P388/S or P388/ADR cells subcutaneously (s.c.) in a volume of 200 μL. Untreated mice are kept in order to determine the lethality of the challenge without chemotherapeutic intervention. Long-term survival is defined as challenged mice that survive the duration of the observation period. Cytochalasins B and D are prepared in suspension form in 2 % carboxymethyl cellulose 1 % tween 20 (CMC/Tw) for intraperitoneal (i.p.) administration. The congeners or the vehicle are administered to leukemia-challenged mice on Days 1-8 following the initial challenge^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Theodoropoulos PA, et al. Cytochalasin B may shorten actin filaments by a mechanism independent of barbed end capping. Biochem Pharmacol. 1994 May 18;47(10):1875-81. [Content Brief] [2]. Trendowski M, et al. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Invest New Drugs. 2015 Apr;33(2):290-9. [Content Brief] [3]. Zhou C, et al. The effect of Cytochalasin B and Jasplakinolide on depolymerization of actin filaments in goose muscles during postmortem conditioning. Food Res Int. 2016 Dec;90:1-7. [Content Brief] [4]. Liang Ma, et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015 Jan;25(1):24-38. [Content Brief]

Cytochalasin B 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	2.0850 mL	10.4251 mL	20.8503 mL	52.1257 mL
	5 mM	0.4170 mL	2.0850 mL	4.1701 mL	10.4251 mL
	10 mM	0.2085 mL	1.0425 mL	2.0850 mL	5.2126 mL
	15 mM	0.1390 mL	0.6950 mL	1.3900 mL	3.4750 mL
	20 mM	0.1043 mL	0.5213 mL	1.0425 mL	2.6063 mL
	25 mM	0.0834 mL	0.4170 mL	0.8340 mL	2.0850 mL
	30 mM	0.0695 mL	0.3475 mL	0.6950 mL	1.7375 mL
	40 mM	0.0521 mL	0.2606 mL	0.5213 mL	1.3031 mL
	50 mM	0.0417 mL	0.2085 mL	0.4170 mL	1.0425 mL
DMSO	60 mM	0.0348 mL	0.1738 mL	0.3475 mL	0.8688 mL
	80 mM	0.0261 mL	0.1303 mL	0.2606 mL	0.6516 mL
	100 mM	0.0209 mL	0.1043 mL	0.2085 mL	0.5213 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cytochalasin B14930-96-2Phomin细胞松弛素B松胞菌素BArp2/3 ComplexActin-related protein 2/3 complexInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Cytochalasin B (Synonyms: 细胞松弛素B; Phomin)

Customer Review

MCE 顾客使用本产品发表的 30 篇科研文献

Cytochalasin B 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Cytochalasin B 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Cytochalasin B (Synonyms: 细胞松弛素B; Phomin)

Customer Review

Cytochalasin B 相关抗体

MCE 顾客使用本产品发表的 30 篇科研文献

Cytochalasin B 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Cytochalasin B 相关抗体:

摩尔计算器

稀释计算器

Cytochalasin B 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z